Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services
|
|
- Aldous Walker
- 5 years ago
- Views:
Transcription
1 Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services DEPRESSION Pharmacological Treatment of Depression NICE guidelines suggest the following stepped care model also see appendix 1 Do not use antidepressants routinely to treat persistent sub-threshold depressive symptoms or mild depression because the risk-benefit ratio is poor. However they should be considered for people with: o A past history of moderate or severe depression OR o Initial presentation of sub-threshold depressive symptoms that have been present for a long period (typically at least 2 years) OR o Sub-threshold depressive symptoms or mild depression that persist(s) after other interventions o Mild depression that complicates the care of a chronic physical health problem Antidepressants should be considered for people presenting with moderate depression. Antidepressants should be considered for people with a chronic physical health problem and presenting with moderate depression, after other interventions have been attempted or rejected by the person Antidepressants should be considered for people presenting with severe depression Antidepressants may be augmented with an atypical antipsychotic (the optimum dose and duration of treatment are unknown) for treatment of psychotic depression. Antidepressants should be given for 3-4 weeks; if there is no response at the optimal dose, then the drug should be changed. If there is a partial response, then continue for 2-4 weeks then reassess. Consider switching the antidepressant if the service user prefers to change or side effects develop or response is inadequate after 6-8 weeks. Be aware that there may be a delay of up to 2 weeks before onset of antidepressant effect. People taking antidepressants should be regularly reviewed, initially at 2 weeks then at intervals of at least 2 to 4 weeks for the first 3 months of treatment, and then at longer intervals if response is good. Antidepressant treatment should be continued for at least 6 months, extending to at least 2 years if there is a high risk of relapse. There is little evidence of difference in efficacy between different drugs but there are differences in side effect profiles; potential for interactions and safety in overdose. If drugs are equal in efficacy and safety, then the cost should be considered. NICE recommends a generic selective serotonin reuptake inhibitor (SSRI) as first choice. There is a possibility of increased anxiety, agitation and suicidal ideation in the first few weeks of antidepressant treatment 1
2 Discuss antidepressant treatment choice, side effects and adherence with the service user and provide appropriate service user information leaflet. Appropriate psychological interventions (e.g. cognitive behavioural therapy, interpersonal therapy) should be considered, usually as an adjunct to antidepressants. Safety Warnings Antidepressants are associated with an initial worsening of anxiety/agitation and an increased risk of suicidal thinking and behaviour. Monitor closely, at 2 weekly intervals, particularly at the start of treatment and when the dose is changed. Patients with high suicide risk or younger than 30 years should be reviewed weekly and then frequently until the risk is no longer clinically important. Abrupt discontinuation (sometimes reduced or missed doses) of antidepressants can lead to a withdrawal syndrome. Symptoms include dizziness, numbness and tingling, gastrointestinal disturbances, headaches, sweating, anxiety and sleep disturbance. Gradual discontinuation is advised. Use antidepressants with care in glaucoma, bipolar disorder, prostate hypertrophy and seizures. Hyponatraemia has been associated with all antidepressants and should be considered in all those who develop drowsiness, confusion, or convulsions while on antidepressants. SSRIs and SNRIs can increase the risk of bleeding. Caution is required in older adults and when used in combination with NSAIDS, aspirin or anticoagulants. Gastroprotection may be required. Epidemiological studies, mainly conducted in patients 50 years of age and older, show an increased risk of bone fractures in patients receiving SSRIs and TCAs Serotonin syndrome (agitation, confusion, tremor, hypereflexia, myoclonus and hyperthermia) and Neuroleptic Malignant Syndrome (NMS)-like reactions can occur with antidepressants particularly when prescribing concomitantly serotonergic drugs agents (including SSRIs, SNRIs, triptans, lithium, tramadol) or with medicinal agents that impair metabolism of serotonin such as MAO-inhibitors (moclobemide) or with serotonin precursors (such as tryptophan supplements). Serotonin syndrome and NMS require emergency management. TCAs are contraindicated in patients with a heart block or during recovery period after myocardial infarction Venlafaxine and duloxetine are contraindicated in uncontrolled hypertension. Caution should be exercised in patients whose underlying conditions might be compromised by increases in blood pressure, e.g., those with impaired cardiac function. Driving For advice on DRIVING and health conditions, see DVLA. It is illegal to drive if medication impairs driving ability. See Drugs and driving: the law. It is an offence for a person to drive with certain levels of some medications in the blood. See for up to date information. A guide to support medical professionals in assessing fitness to drive can be found at 2
3 Adverse Effects and Interactions SSRIs are better tolerated and safer in overdose than other antidepressants. Common side effects of SSRIs are headache, nausea, and anxiety/agitation, especially when starting treatment (usually settle on continued treatment). Other side effects are insomnia, tremor, akathisia, sweating, paraethesias, sexual dysfunction, including diminished libido and difficulty with erection and orgasm, muscle/joint pain, hyponatraemia, bruising/bleeding, weight changes and manic or psychotic symptoms. Tricyclic antidepressants have similar efficacy to SSRIs but are more likely to be discontinued because of side-effects and are toxic in overdose. Common side effects of tricyclics include anxiety, drowsiness, dizziness, agitation, confusion, anticholinergic effects (dry mouth, constipation, urinary retention and blurred vision); cardiovascular effects (hypotension, tachycardia, arrhythmias and other ECG changes - baseline ECG is advised, where appropriate); hepatic effects, changes in blood sugar, increased appetite, weight gain and sexual dysfunction can occur. Monoamine Oxidase Inhibitors (MAOIs) can have dangerous interactions with some foods and drugs, and should be reserved for initiation by consultants. Service users prescribed MAOIs require careful monitoring (blood pressure) and advice on dietary and drug interactions. When changing antidepressants, a suitable washout period (usually at least 14 days) should be allowed before or after using MAOIs. Mirtazapine has few antimuscarinic effects, but causes sedation during initial treatment and is associated with weight gain and blood dyscrasias. Relevant NICE Guidance NICE Clinical Guideline (CG90). Depression: the treatment and management of depression in adults (update). October Last updated: April Available at UNDER REVIEW. NICE Clinical Guideline (CG91). Depression in adults with a chronic physical health problem: Treatment and management. October Available at NICE clinical guideline (CG28). Depression in children and young people. September Last updated: September Available at: NICE Pathways: Depression NICE quality standards: Depression in adults quality standard Mar Depression in children and young people Sept
4 Depression First Line: Relative Cost Notes Citalopram Has less drug/drug interactions; prolongs QT interval; contraindicated with other drugs that prolong QT Escitalopram Has less drug/drug interactions; prolongs QT interval; contraindicated with other drugs that prolong QT Sertraline Sertraline has a superior tolerability and is preferred in cardiac disease Mirtazapine Tabs/Orodispersible / Fluoxetine Long half life useful if compliance is an issue. Drug/drug interactions common - Second Line: Relative Cost Notes Useful where weight is not a concern and sedation is preferable; caution in liver impairment. Rare cases of bone marrow depression. Use with caution where there are risk factors for QT prolongation Venlafaxine Tablets XL capsules/tablets More toxic in overdose than SSRIs; higher risk of discontinuation reaction. Dose-related increases in blood pressure have been commonly reported with venlafaxine. Prolonged release formulations XL are more expensive than immediately released formulations. Lofepramine Least cardiotoxic of TCAs Trazodone Useful in anxiety and agitation where sedation is required Significant costs associated with trazodone liquid. Duloxetine Brand Care needed to use correct dosage regimen; associated with nausea and headache, and can also increase blood pressure. Paroxetine Higher incidence of discontinuation symptoms. Drug/drug interactions common Vortioxetine For major depressive episodes in adults whose condition has responded inadequately to 2 antidepressants within the current episode Third Line: Relative Cost Notes [Discuss third line options with Consultant before prescribing] Amitriptyline Titrate slowly toxic in overdose Fluvoxamine Nausea a problem; drug/drug interactions common; Caution in hepatic or renal impairment; Bradycardia with ECG changes has been noted; Imipramine Less sedating than other tricyclics with moderate antimuscarinic activity; Expensive Clomipramine Useful if OCD symptoms are present as well Doxepin Moderate sedative effects Moclobemide Use alone need to be careful with diet difficult to switch from 4
5 Depression continued Fourth Line: Relative Cost Notes [Seek Consultant Opinion before prescribing] Phenelzine Dietary problems. Washout period required when switching. Useful for atypical depression Mianserin Regular blood counts needed Nortriptyline Less postural hypotension and lower cardiotoxicity than other tricyclics; Expensive Agomelatine Liver function test required before and during use; Expensive; Specialist initiation and hospital use only Reboxetine Poor response rate and low tolerability; May lower serum potassium; Not licensed in older adults. Other Notes [Seek Consultant Opinion before prescribing] ECT Consider for severe, life-threatening depression when a rapid response is required, or when other treatments have failed OR for moderate depression unresponsive to multiple drug treatments and psychological treatment Benzodiazepine Tablets s Short-term treatment (usually no longer than 2 weeks) if anxiety, agitation and/or insomnia are a problem; Avoid in chronic anxiety symptoms; Use with caution in people at risk of falls. Augmentation Relative Cost Notes [Seek Consultant Opinion before prescribing] Add Lithium - Use in treatment resistant depression baseline and routine monitoring and blood tests needed Add Tryptophan Use in treatment resistant depression blood tests needed; Unlicensed in the UK; Named patient only Add Antipsychotic - Useful for depression with psychotic symptoms; monitor weight, lipids, glucose levels, side effects Not Recommended Notes Dosulepin Avoid due to increased cardiac risk and toxicity in overdose. Should not be started in new patients. St John s Wort - Avoid due to uncertainty about appropriate dose, persistence of effect, variation in available preparations and risk of serious interactions with other drugs Augmentation with lamotrigine, carbamazepine, buspirone, pindolol - Not routinely recommended because of insufficient evidence of effectiveness Trimipramine Significant costs associated with trimipramine prescribing. 5
6 Treatment of Resistant or Refractory Depression This requires a flexible approach Escalate antidepressant doses for an adequate duration Switch drugs ensuring that all drug classes have been tried optimally Augment the antidepressant with other drugs or combine two antidepressants Assure compliance Manage ADRs that may reduce compliance Monitor and review outcome of treatment Offer high-intensity psychological interventions eg CBT Options include 1 st choice Add lithium well established recommended by NICE Use combinations of antidepressants e.g. mirtazapine & venlafaxine OR an SSRI Add liothyronine (T3) 20mcg 50mcg daily may be better tolerated than lithium Augmentation of current therapy with bupropion or buspirone (less evidence-based) Use other antidepressants e.g. nortriptyline (TCA) or tranylcypromine (MAOI) 2 nd choice 3 rd choice Add lamotrigine, max 200mg daily SSRI and up to 60mg buspirone daily Venlafaxine >225mg daily recommended by NICE; Consider ECT for severe, life-threatening depression when a rapid response is required, or when other treatments have failed OR for moderate depression unresponsive to multiple drug treatments and psychological treatment. For further options please contact the Pharmacy department 6
7 Usual Recommended Treatment of Depression in Chronic Medical Conditions Co-morbidity Post stroke Diabetes Cardiovascular disease Epilepsy Hepatic Old age Renal impairment Elderly Musculoskeletal disease Migraine Recommended treatment In all chronic conditions any possible drug interactions must be considered as a matter of priority SSRIs Mirtazapine (small effect on INR causing an increase to INR) SSRIs fluoxetine best supported by data Venlafaxine Mirtazapine SSRIs preferably sertraline especially if also prescribed flecainide, propafenone. SSRIs not recommended if also prescribed warfarin, heparin or aspirin Mirtazapine Check choices with Medicines Information before use of any antidepressant Paroxetine SSRIs Mirtazapine In Parkinson s disease do not use SSRIs with MAO-B inhibitors e.g. selegiline Check choices with Medicines Information before use of any antidepressant Consider lower doses and increase slowly. Also consider co-morbidity SSRIs not recommended to be used with NSAIDs. If essential use a gastroprotective agent at the same time In people receiving triptans use mirtazapine / trazodone / mianserin or reboxetine If the above options for recommended treatments in co-morbidity have been used without an improvement in symptoms, then please contact the Pharmacy Department for more detailed and individualised advice. 7
8 Appendix 1 The Stepped-Care Model The least intrusive, most effective intervention is provided first. If a person does nor benefit from that intervention, or declines an intervention, they should be offered an appropriate intervention from the next step Focus of the intervention Nature of the intervention Step 4 Severe and complex depression 1 ; risk to life; severe self neglect Medication, high-intensity psychological interventions, electroconvulsive therapy, crisis service, combined treatments, multiprofessional and inpatient care Step 3 Persistent subthreshold depressive symptoms or mild to moderate depression with inadequate response to initial interventions; moderate and severe depression Medication, high-intensity psychological interventions, combined treatments, collaborative care 2 and referral for further assessment and interventions Step 2 Persistent subthreshold depressive symptoms; mild to moderate depression Low-intensity psychological and psychosocial interventions, medication and referral for further assessment and interventions Step 1 All known and suspected presentations of depression Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions 1 Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms and/or is associated with significant psychiatric comorbidity or psychosocial factors 2 only for depression where the person also has a chronic physical health problem and associated functional impairment 8
9 Appendix 2 Relative Side Effects of Antidepressants Drug Some of the main side effects Drowsiness Weight gain Nausea Anticholinergic Sexual Cardiac effects effects problems Citalopram Sertraline Fluoxetine Escitalopram Mirtazapine o o o + Venlafaxine Moclobemide Amitriptyline Clomipramine Imipramine Nortriptyline Lofepramine Trazodone o Paroxetine Fluvoxamine Reboxetine o o o Duloxetine Vortioxetine Phenelzine Agomelatine o o o o o ++ Tryptophan + o + o o + Lithium o o = relatively common; ++ = moderately common + = uncommon 0 = little or no effect 9
10 References 1. NICE Clinical Guideline (CG90). Depression: the treatment and management of depression in adults (update) NICE Clinical Guideline (CG91). Depression in adults with a chronic physical health problem: Treatment and management NICE clinical guideline (CG28). Depression in children and young people (rapid update March 2015). 4. NICE technology appraisal guidance. Vortioxetine for treating major depressive episodes (TA367)November BAP Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines BNF online (British Medical Association and the Royal Pharmaceutical Society of Great Britain). Online BNF online at: 7. Martindale The complete drug reference online at: [subscription required] 8. SPCs for all the drugs referred to in this guideline can be found in the Electronic Medicines Compendium ( 9. Bazire. Psychotropic Drug Directory Lloyd-Reinhold Communications. 10. The Maudsley Guidelines 12 th edition and online at The Maudsley Guidelines 11th edition and online at (NHS athens password required) 11. MHRA Drug Safety Update. Antidepressants: risk of fractures MHRA Drug Safety Update. Agomelatine (Valdoxan): risk of liver toxicity reminder to test liver function before and during treatment MHRA Drug Safety Update. Citalopram and escitalopram: QT interval prolongation new maximum daily dose restrictions (including in elderly patients), contraindications, and warnings MHRA Drug Safety Update. Antidepressants: suicidal thoughts and behaviour - summary report NHS England. Items which should not routinely be prescribed in primary care: Guidance for CCGs. 10
Volume 4; Number 5 May 2010
Volume 4; Number 5 May 2010 CLINICAL GUIDELINES FOR ANTIDEPRESSANT USE IN PRIMARY AND SECONDARY CARE Lincolnshire Partnership Foundation Trust in conjunction with Lincolnshire PACEF have recently updated
More informationGuidelines on Choice and Selection of Antidepressants for the Management of Depression
Guidelines on Choice and Selection of Antidepressants for the Management of Depression 1. Introduction This guidance should be considered as part of a stepped care approach in the management of depressive
More informationGuidelines on Choice and Selection of Antidepressants for the Management of Depression
Working in partnership: Hertfordshire Partnership University NHS Foundation Trust East and North Hertfordshire Clinical Commissioning Group Herts Valleys Clinical Commissioning Group Guidelines on Choice
More informationAntidepressant Treatment of Depression
Antidepressant Treatment of Depression PLEASE REFER TO INTEGRATED CARE PATHWAY FOR INFORMATION RELATING TO THE OVERALL MANAGEMENT OF DEPRESSION SSRI s are first choice agents because they are as effective
More informationGuidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive
More informationKEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.
KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised
More informationAppendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over)
Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over) Introduction / Background Treatment comes after diagnosis Diagnosis is based on
More informationClinical Guideline / Formulary Document Pharmacy Department Medicines Management Services
Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services ANXIETY DISORDERS This guideline covers a range of anxiety disorders, including generalised anxiety disorder, social
More informationClinical guideline Published: 28 October 2009 nice.org.uk/guidance/cg91
Depression in adults with a chronic physical health problem: recognition and management Clinical guideline Published: 28 October 2009 nice.org.uk/guidance/cg91 NICE 2018. All rights reserved. Subject to
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More informationGREATER MANCHESTER INTERFACE PRESCRIBING GROUP
GREATER MANCHESTER INTERFACE PRESCRIBING GROUP On behalf of the GREATER MANCHESTER MEDICINES MANAGEMENT GROUP SHARED CARE GUIDELINE FOR THE PRESCRIBING OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)
More informationGuidance on the use of Antidepressants for the Treatment of Unipolar Depression and Anxiety Spectrum Disorders in adults (Version 3 October 2014)
Guidance on the use of Antidepressants for the Treatment of Unipolar Depression and Anxiety Spectrum Disorders in adults (Version 3 October 2014) Date of Preparation: September 2014 Date for next full
More informationAnti-Depressant Medications
Anti-Depressant Medications A Introduction: This topic may be a little bit underestimated here in Jordan, while in western countries it has more significance. The function of anti-depressants is to change
More information4.3 Antidepressants (ADDs) BNF Section 4.3
4.3 Antidepressants (ADDs) BNF Section 4.3 The aim of this guidance is to provide prescribing guidance and highlight good practice. It is not intended to be a comprehensive practice treatment guideline.
More informationPharmaceutical Interventions. Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007
Pharmaceutical Interventions Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007 Outline Overview Overview of initial workup and decisions in elderly depressed individual
More informationGuidance on the use of Antidepressants for the Treatment of Unipolar Depression and Anxiety Spectrum Disorders in adults (Version 4.
Guidance on the use of Antidepressants for the Treatment of Unipolar Depression and Anxiety Spectrum Disorders in adults (Version 4.1 December 2018) Date of Preparation: January 2018 (with addition of
More informationDepression in adults: treatment and management
1 2 3 4 Depression in adults: treatment and management 5 6 7 8 Appendix V3: recommendations that have been deleted of changed from 2009 guideline Depression in adults: Appendix V3 1 of 22 1 Recommendations
More informationDepression: management of depression in primary and secondary care
Issue date: December 2004, with amendments April 2007 Quick reference guide (amended) Depression: management of depression in primary and secondary care Amendment of recommendations concerning venlafaxine:
More informationReducing the Anxiety of Pediatric Anxiety Part 2: Treatment
Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Lisa Lloyd Giles, MD Medical Director, Behavioral Consultation, Crisis, and Community Services Primary Children s Hospital Associate Professor,
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care Rebecca D. Lewis, DO OOA Summer CME Oklahoma City, OK 6 August 2017 Objectives Understand the epidemiology of depression. Recognize factors to help choose antidepressants.
More informationClinical guideline Published: 28 October 2009 nice.org.uk/guidance/cg90
Depression in adults: recognition and management Clinical guideline Published: 28 October 2009 nice.org.uk/guidance/cg90 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationBRIEF SUMMARY CONTENT
Page 1 of 17 Brief Summary GUIDELINE TITLE Depression. The treatment and management of depression in adults. BIBLIOGRAPHIC SOURCE(S) National Collaborating Centre for Mental Health. Depression. The treatment
More informationPRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA
CASE #1 PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA OBJECTIVES Epidemiology Presentation in older adults Assessment Treatment
More informationClinical guideline Published: 28 October 2009 nice.org.uk/guidance/cg90
Depression in adults: recognition and management Clinical guideline Published: 28 October 2009 nice.org.uk/guidance/cg90 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationDepression: selective serotonin reuptake inhibitors
Depression: selective serotonin reuptake inhibitors Selective serotonin reuptake inhibitors (SSRIs) are considered first-line treatment for the majority of patients with depression. citalopram and fluoxetine
More informationDocument Title Pharmacological Management of Generalised Anxiety Disorder
Document Title Pharmacological Management of Generalised Anxiety Disorder Document Description Document Type Policy Service Application Trust Wide Version 1.1 Policy Reference no. POL 201 Lead Author(s)
More informationSECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS
SECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS Formulary and Prescribing Guidelines 9.1 Introduction Movement disorders and extrapyramidal side effects can manifest in the
More informationDementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist
Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution
More informationDepression in Pregnancy
TREATING THE MOTHER PROTECTING THE UNBORN A MOTHERISK Educational Program The content of this program reflects the expression of a consensus on emerging clinical and scientific advances as of the date
More informationNeuropathic Pain Treatment Guidelines
Neuropathic Pain Treatment Guidelines Background Pain is an unpleasant sensory and emotional experience that can have a significant impact on a person s quality of life, general health, psychological health,
More informationPharmacotherapy of depression
Pharmacotherapy of depression Stuff you already know Stuff you probably know Stuff you possibly don t know Stuff you thought you knew but are mistaken about How long does it take for antidepressants
More informationMental illness A Broad Overview. Dr H Pathmanandam March 2017
Mental illness A Broad Overview Dr H Pathmanandam March 2017 Introduction Mental disorders are common in primary and secondary care Many are not recognised and not treated Some receive unnecessary or inappropriate
More informationPresentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationANTIDEPRESSANTS IN USE IN CLINICAL PRACTICE
Medicinska naklada - Zagreb, Croatia Conference paper ANTIDEPRESSANTS IN USE IN CLINICAL PRACTICE Mark Agius 1 & Hannah Bonnici 2 1 Clare College, University of Cambridge, Cambridge, UK 2 Hospital Pharmacy
More informationPregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)
Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned
More informationThis initial discovery led to the creation of two classes of first generation antidepressants:
Antidepressants - TCAs, MAOIs, SSRIs & SNRIs First generation antidepressants TCAs and MAOIs The discovery of antidepressants could be described as a lucky accident. During the 1950s, while carrying out
More information9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationAffective or Mood Disorders. Dr. Alia Shatanawi March 12, 2018
Affective or Mood Disorders Dr. Alia Shatanawi March 12, 2018 Affective or Mood Disorders Reactive Depression. Secondary: Medical Neurological Drugs Major (Endogenous) Depression = Unipolar: Depressed
More informationAntidepressant Pharmacology An Overview
Figure 1. Antidepressant Pharmacology An Overview Source: NEJM 2005;353:1819-34 Figure 2. 1 Figure 3: Antidepressant Pharmacology pictures: Weak inhibition Bupropion NOTE: CYP enzymes noted are those inhibited
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care R E B E C C A D. L E W I S, D O O O A S U M M E R C M E B R A N S O N, M O 1 5 A U G U S T 2 0 1 5 Objectives Understand the epidemiology of depression. Recognize
More informationQuick Guide to Common Antidepressants-Adults
Quick Guide to Common Antidepressants-Adults Medication Therapeutic Range (mg/day) Initial Suggested Serotonin Reuptake Inhibitors (SSRIs) All available as generic FLUOXETINE (Prozac) CITALOPRAM (Celexa
More informationPHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES
PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES Table of Contents Print TABLE OF CONTENTS Drug Page Number Anafranil... 2 Asendin... 4 Celexa... 4 Cymbalta... 6 Desyrel... 8 Effexor...10 Elavil...14
More informationPSYCHIATRIC MANAGEMENT IN PRIMARY CARE. Dr Fayyaz Khan MBBS, MRCPsych, MSc Consultant Psychiatrist (Locum) Mersey Care NHS Trust
PSYCHIATRIC MANAGEMENT IN PRIMARY CARE Dr Fayyaz Khan MBBS, MRCPsych, MSc Consultant Psychiatrist (Locum) Mersey Care NHS Trust Areas to cover Mood Disorders Anxiety Disorders Miscellaneous Conditions
More informationTreatment Options for Bipolar Disorder Contents
Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8
More information3. Atypical antidepressants
3. Atypical antidepressants Bupropion, mirtazapine, nefazodone & trazodone. Mixed group that act at several different sites. Bupropion Acts as a weak dopamine & NE reuptake inhibitor. Has short half-life.
More informationPsychotropic Medication Use in Dementia
Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,
More informationInformation leaflet for primary care: Agomelatine
Information leaflet for primary care: Agomelatine Background information Agomelatine is an antidepressant indicated for the treatment of major depressive episodes in adults. Agomelatine is a melatonin
More informationMMG004 GUIDELINES FOR THE USE OF HIGH DOSE VENLAFAXINE AND THE COMBINATION OF VENLAFAXINE AND MIRTAZAPINE IN THE TREATMENT OF DEPRESSION
MMG004 GUIDELINES FOR THE USE OF HIGH DOSE VENLAFAXINE AND THE COMBINATION OF VENLAFAXINE AND MIRTAZAPINE IN THE TREATMENT OF DEPRESSION Page 1 of 13 Table of Contents Why we need this Guideline... 3 What
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Neuropathic pain pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist
More informationDiagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD
Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty
More informationMedication management of anxiety & depression. Dr Katie Simpson GP Mental health lead East Berks CCG
Medication management of anxiety & depression Dr Katie impson GP Mental health lead East Berks CCG NICE guidelines for Anxiety tepped Care RIs and NRIs in Anxiety disorders RI ertraline Citalopram Fluoxetine
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
Step 3: GAD with marked functional impairment or that has not improved after step 2 interventionsentions bring together everything NICE says on a topic in an interactive flowchart. are interactive and
More informationGeneralized Anxiety Disorder ( DSM -IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6
Generalized Anxiety Disorder ( DSM -IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6 months and which the person finds difficult to control.
More informationPharmacological Treatment of Anxiety & Depressive Disorders
Pharmacological Treatment of Anxiety & Depressive Disorders Dr Gary Jackson (MB BCh FRCPsych) Consultant Psychiatrist The Priory Hospital Chelmsford Wellesley Hospital Southend-on-Sea Medical Secretary:
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Shared Care Guideline for the prescribing and monitoring of Antipsychotics for the treatment of Schizophrenia and psychotic symptoms in children and adolescents Scope: Pennine
More informationBRIEF ANTIDEPRESSANT OVERVIEW. Casey Gallimore, Pharm.D., M.S.
BRIEF ANTIDEPRESSANT OVERVIEW Casey Gallimore, Pharm.D., M.S. Antidepressant Medication Classes First Generation Tricyclic Antidepressants (TCAs) Monoamine Oxidase Inhibitors (MAOIs) Second Generation
More informationPerinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs
Perinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs (Version 3 January 2015) Principal Author: Dr Jenny Cooke Consultant Psychiatrist, Brighton & Hove Perinatal Mental Health Service
More informationFormulary and Clinical Guideline Document Pharmacy Department Medicines Management Services
Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services VIOLENCE, AGGRESSION OR SEVERE BEHAVIOURAL DISTURBANCE Introduction During an acute episode or illness, some
More informationAtomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD)
Atomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD) Section 1: Shared Care arrangements and responsibilities Section 1.1 Agreement to transfer of prescribing
More informationPsychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI
Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Lithium Treatment in Adults aged 18-65 years Scope: Pennine Care NHS Foundation Trust NHS Bury NHS Oldham NHS Heywood, Middleton and Rochdale NHS Stockport NHS Tameside & Glossop
More informationHazard ratio for coronary heart disease mortality for SMI patients versus controls (18-49 yrs) Hazard ratio for stroke
By Michael Dixon Contents Background to Bipolar Disorder and cardiac risk Mood stabilisers and cardiac risk factors Background to Depression and cardiac risk Antidepressants and cardiac risk factors Any
More informationMedication for Anxiety and Depression. PJ Cowen Department of Psychiatry, University of Oxford
Medication for Anxiety and Depression PJ Cowen Department of Psychiatry, University of Oxford Topics Medication for anxiety disorders Medication for first line depression treatment Medication for resistant
More informationNorpramin (desipramine)
Generic name: Desipramine Available strengths: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg tablets Available in generic: Yes Drug class: Tricyclic antidepressant General Information Norpramin (desipramine)
More informationElavil (amitriptyline)
Generic name: Amitriptyline Available strengths: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg tablets; 10 mg/ml injection Available in generic: Yes Drug class: Tricyclic antidepressant General Information
More informationPrimary Care Management of Depression. John Briles, MD, Medical Director October 11, 2017
John Briles, MD, Medical Director October 11, 2017 Molina Healthcare of Michigan uses a HEDIS measure for Antidepressant Medication Management (AMM) to measure how well treating providers (PCPs) appropriately
More informationAntidepressants Choosing the Right One
Antidepressants Choosing the Right One Dr Lim Boon Leng Consultant Psychiatrist Dr BL Lim Centre For Psychological Wellness #09-09, Gleneagles Medical Centre, 6 Napier Rd, S258499 www.psywellness.com.sg
More informationDrugs for Emotional and Mood Disorders Chapter 16
Drugs for Emotional and Mood Disorders Chapter 16 NCLEX-RN Review Question 1 Choices Please note Question #1 at the end of Ch 16 pg 202 & Key pg 805 answer is #4 1. Psychomotor symptoms 2. Tachycardia,
More informationTREATING MAJOR DEPRESSIVE DISORDER
TREATING MAJOR DEPRESSIVE DISORDER A Quick Reference Guide Based on Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Second Edition, originally published in April 2000.
More informationObjectives. Objectives. A practice review. 02-Nov-16 MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS
MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS Jon-Paul Khoo What is treatment resistance really? Database review 328 consecutive non-remitted MDD patients referred for private
More informationAntidepressants: Prof. Riyadh Al_Azzawi F.R.C.Psych
Antidepressants: Prof. Riyadh Al_Azzawi F.R.C.Psych A. Heterocyclic antidepressants: (tricyclic and tetracyclic ), e.g.amitryptaline,imipramine. B. Monoamine oxidase inhibitors(m.a.o.i), e.g.phenelzine.
More informationBournemouth, Dorset and Poole Prescribing Forum
SHARED CARE GUIDELINES FOR PRESCRIBING OF METHYLPHENIDATE IN ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN INDICATION Methylphenidate is generally regarded as a first line choice of treatment for
More informationPRESCRIBING GUIDELINES
The Maudsley The South London and Maudsley NHS Foundation Trust & Oxleas NHS Foundation Trust PRESCRIBING GUIDELINES 10th Edition David Taylor Carol Paton Shitij Kapur informa healthcare Contents Authors
More informationSmoking Cessation Pharmacotherapy Guidelines
Smoking Cessation Pharmacotherapy Guidelines INTRODUCTION This guideline is based on public health guidance 10 Smoking Cessation Services issued by the National Institute for Health and Clinical Excellence
More informationSouth London and the Maudsley NHS Foundation Trust Medicines Formulary
South London and the Maudsley NHS Foundation Trust Medicines Formulary Medicine Formulations Restrictions Additional Information / Related NICE Technology Appraisal 4.1 Hypnotics and anxiolytics 4.1.1
More informationMentoring Session: Participant Cases
Handout for the Neuroscience Education Institute (NEI) online activity: Mentoring Session: Participant Cases The Case: 55-year-old patient with depression and anxiety The Question: What to do when antidepressants
More informationChildren s Hospital Of Wisconsin
Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,
More informationBupropion HCl, bupropion hydrobromide Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XL
Bupropion Generic names Available brands Available strengths and formulations Available in generic Bupropion HCl, bupropion hydrobromide Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XL 75-mg
More informationMirtazapine GENERAL INFORMATION. 15-mg, 30-mg, and 40-mg orally disintegrating tablets (SolTab) Available in generic
Mirtazapine Generic name Available brands Available strengths and formulations Available in generic Mirtazapine Remeron, Remeron SolTab 7.5-mg, 15-mg, 30-mg, and 45-mg tablets 15-mg, 30-mg, and 40-mg orally
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION Naltrexone is used as part of a comprehensive programme of treatment against alcoholism to reduce the
More informationAntidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry
Antidepressant Medication Strategies We ve Come a Long Way or Have We? Joe Wegmann, PD, LCSW The PharmaTherapist Joe@ThePharmaTherapist.com 504.587.9798 www.pharmatherapist.com Are you receiving our free
More informationS H A R E D P R E S C R I B I N G G U I D E L I N E
S H A R E D P R E S C R I B I N G G U I D E L I N E Introduction This shared prescribing guideline for the second generation antipsychotic medications listed above has been developed with due consideration
More informationSupplementary Online Content
Supplementary Online Content Renoux C, Vahey S, Dell Aniello S, Boivin J-F. Association of selective serotonin reuptake inhibitors with the risk for spontaneous intracranial hemorrhage. JAMA Neurol. Published
More informationMedication Guide SARAFEM (SAIR-a-fem) (fluoxetine hydrochloride) Tablets
Medication Guide SARAFEM (SAIR-a-fem) (fluoxetine hydrochloride) Tablets Read the Medication Guide that comes with SARAFEM before you start taking it and each time you get a refill. There may be new information.
More informationPamelor (nortriptyline)
Generic name: Nortriptyline Available strengths: 10 mg, 25 mg, 50 mg, 75 mg capsules; 10 mg/5 ml oral solution Available in generic: Yes Drug class: Tricyclic antidepressant General Information Pamelor
More informationElements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Generalised anxiety disorder Generalised anxiety disorder (GAD) is an umbrella term that covers a wide range of anxiety disorders
More informationMood Disorders.
Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationNortriptyline vs amitriptyline in elderly
Nortriptyline vs amitriptyline in elderly Amitriptyline (Elavil ) vs other antidepressants - comparative analysis amitriptyline vs divalproate, amitriptyline vs trazodone. Learn what other patients are
More informationTreat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused
Psychiatric Drugs Psychiatric Drugs Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally or abused Benzodiazepines
More informationTofranil and Tofranil-PM (imipramine)
Tofranil and Tofranil-PM (imipramine) Generic name: Imipramine Available strengths: 10 mg, 25 mg, 50 mg tablets; 75 mg, 100 mg, 125 mg, 150 mg capsules (Tofranil-PM) Available in generic: Yes Drug class:
More informationSANDOMIGRAN (pizotifen malate)
SANDOMIGRAN (pizotifen malate) S N CH 3 Pizotifen. COOH CH OH CH 2 COOH MALATE DESCRIPTION Pizotifen is a cycloheptathiophene derivative structurally related to cyproheptadine and the tricyclic antidepressants.
More informationTreatment-resistant depression in primary care
Treatment-resistant depression in primary care Interprofessional CME, October 2017 Brian J. Mickey, MD, PhD Associate Professor School of Medicine Department of Psychiatry Disclosures Speakers bureau:
More informationClinical Guideline for the Management of Bipolar Disorder in Adults
Clinical Guideline for the Management of Bipolar Disorder in Adults Goal: To improve the quality of life of adults with bipolar disorder Identification and Treatment of Bipolar Disorder Criteria for Diagnosis:
More informationAcute Treatment: 40 mg/day (20 mg twice daily) to 60 mg/day (once daily or as 30 mg twice daily); Maintenance Treatment: 60 mg/day
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Cymbalta safely and effectively. See full prescribing information for Cymbalta. Cymbalta (duloxetine
More informationPSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer
PSYCHIATRIC DRUGS Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally
More informationTricyclic Antidespressants: Actions
Introductory Clinical Pharmacology Chapter 24 Antidepressant Drugs Tricyclic Antidespressants: Actions Increase sensitivity in postsynaptic alpha (α)-adrenergic, serotonin receptors Decrease sensitivity
More informationTOP APS DRUGS TRAZODONE BRAND NAMES: OLEPTRO, DESYREL (DIVIDOSE) & TRIALODINE
trazodone TOP APS DRUGS TRAZODONE BRAND NAMES: OLEPTRO, DESYREL (DIVIDOSE) & TRIALODINE Pharmacodynamics study of what a drug does to the body Studies show that trazodone selectively inhibits neuronal
More informationANTI-DEPRESSANT MEDICATIONS
ANTI-DEPRESSANT MEDICATIONS This information is not intended to be a substitute for medical advice. It s purpose is solely informative. If your client or yourself are taking antidepressants, do not change
More informationCommon Antidepressant Medications for Adults
(and Citalopram (Celexa) Escitalopram (Lexapro) Fluoxetine (Prozac) Fluoxetine Weekly (Prozac Weekly) 20 in AM w/ food (10 mg in elderly or those w/ panic disorder) 20 40 40 (If age >60yo, max 20) 10 10
More information